Lantus

Insulin glargine

Adults, adolescents & childn ≥6 yr w/ DM where treatment w/ insulin is required.

SC Administer once daily at the same time everyday. Dose & timing of dose should be individually adjusted.

Hypersensitivity.

Not the insulin of choice for the treatment of diabetic ketoacidosis. Switching a patient to another type or brand of insulin should be done under strict medical supervision & may require change in dose. Perform continuous inj site rotation to reduce the risk of developing lipodystrophy & cutaneous amyloidosis. Monitor blood glucose after change in inj site & consider dose adjustment of antidiabetics. Patients in whom hypoglycaemic episodes might be of particular clinical relevance (eg, those w/ significant stenoses of coronary arteries or of blood vessels supplying the brain, & proliferative retinopathy particularly if not treated w/ photocoagulation). Patients w/ diminished warning symptoms of hypoglycaemia (eg, those w/ marked improvement in glycaemic control, w/ gradual development of hypoglycaemia, elderly, after transfer from animal to human insulin, w/ autonomic neuropathy, long history of diabetes, psychiatric illness); may result in severe hypoglycemia (& possibly loss of consciousness). Closely monitor patients & adjust dose, if necessary, in case of factors that increase susceptibility to hypoglycaemia eg, change in inj area, improved insulin sensitivity (eg, by removal of stress factors), unaccustomed, increased or prolonged physical activity, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, in hypothyroidism & in anterior pituitary or adrenocortical insufficiency). Intercurrent illness requires intensified metabolic monitoring. May cause insulin Abs to form. Concomitant use w/ other medicines. Contains <1 mmol (23 mg) Na/dose. May impair ability to drive or operate machinery. Perform continuous inj site rotation. Hepatic & moderate/severe renal impairment. Pregnancy & lactation. Childn <6 yr.

Hypoglycaemia. Lipohypertrophy, inj site reactions.

Enhanced blood glucose-lowering effect w/ oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. May potentiate/weaken blood glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Pentamidine may cause hypoglycaemia, sometimes followed by hyperglycaemia. Reduced/absent signs of adrenergic counter regulation w/ β-blockers, clonidine, guanethidine & reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

POM